



Real World Testing Plan for PulseCheck ED

CY 2024


Developer Attestation

This Real World Testing plan is complete with all required elements, including measures that address all certification criteria and care settings. All information in this plan is up to date and fully addresses the health IT developer's Real World Testing requirements.

Authorized Representative Name: Romel Ursua

Authorized Representative Email: PicisMU@picis.com

Authorized Representative Phone: 224-217-9766

Authorized Representative Signature: 

Date: 10.24.2023

Contents

Developer Attestation.....	1
General Information	3
Timeline and Milestones for Real World Testing CY2024	3
Standards Updates including Standards Version Advancement Process (SVAP) and United States Core Data for Interoperability (USCDI).....	4
Justification for Real World Testing Approach	5
Real World Testing Measurements	5

General Information

Plan Report ID Number: xxx

Developer Name: Picis PulseCheck, a business unit of Harris Computer Systems

Product Name(s): PulseCheck ED

Version Number(s): 6.0, 7.0

Product List (CHPL) ID(s): 15.02.04.3070.Puls.06.02.1.211216, 15.02.04.3070.Puls.07.03.1.211216

Developer Real World Testing Page URL: <https://pulsechecked.com/ONC-certified>

Timeline and Milestones for Real World Testing CY2024

Key Milestone	Date/Timeframe
Develop candidate list of clients to assist with the Real World Testing	Q1 2024
Release of documentation for the Real World Testing to be provided to authorized representatives and providers utilizing e-prescribing and/or Syndromic Surveillance within PulseCheck ED	Q2 2024
Collection of information as laid out by the plan	Q2 and Q3 2024
Follow-up with providers and authorized representatives to understand any issues arising with the data	Q2, Q3, Q4 2024 (as needed)
End of Real-World Testing period/final collection of all data for analysis	January 2025
Analysis and report creation	January 2025
Submit Real World Testing report to ACB	February 2025

Standards Updates including Standards Version Advancement Process (SVAP) and United States Core Data for Interoperability (USCDI))

For CY 2023, we are planning on certifying on updated standards for § 170.315(b)(3).

Standard (and version)	NCPDP Script
Updated certification criteria and associated product	§ 170.315(b)(3)
Health IT Module CHPL ID	15.02.04.3070.Puls.06.02.1.211216 15.02.04.3070.Puls.07.03.1.211216
Method used for standard update	ACB direct notification
Date of ONC-ACB notification	October 2021
Date of customer notification (SVAP only)	N/A
Conformance measure	NCPDP Script Implementation Guide version 2017071
USCDI-updated certification criteria (and USCDI version)	N/A

Justification for Real World Testing Approach

In each measurement description, we elaborate specifically on our justification for choosing this measure and the expected outcomes. All measurements were chosen to best evaluate compliance with the certification criteria and interoperability of exchanging electronic health information (EHI) within the certified EMR.

We will gain further insight into how often electronic prescriptions and syndromic surveillance interoperability features are being used, as well as their compliance to the requirement. This information can further support our customers in Emergency Department settings and the patient populations they serve as we determine real world interoperability and usability, specifically how often clinicians use these services in their intended applications.

Real world testing will be conducted using PulseCheck ED versions 6.0, and 7.0. Results for the two versions will be combined into one result upon creation of the Real World Test Results Report.

Real World Testing Measurements

The measurements for our real world testing plan are described below. Each measurement contains:

- Associated ONC criteria
- Description of the measurement/metric
- Justification for the measurement/metric
- Expected outcomes in testing for the measurement/metric
- Care settings which are targeted with the measurement/metric

For each measure, we elaborate specifically on our justification for choosing the measure and the expected outcomes. All measurements were chosen to best evaluate compliance with the certification criteria and interoperability of exchanging electronic health information (EHI).

Care Settings Targeted

PulseCheck ED is an emergency department electronic medical record (ED EMR) that supports deployment and tracking of features used within the Emergency Department setting.

Real World Testing Measure #1

Measurement: Success rate of eRx messages over pertinent timeframe

Associated certification criteria: §170.315(b)(3) Electronic prescribing

Description: A 75%+ success rate (25% failure rate accounts for pharmacy or intermediary downtimes and intermittent connection issues) will be reported based on data from an identified group of clients.

Justification: The metric provides proof that NCPDP SCRIPT standards are used with PulseCheck ED to send prescription information from clinicians to pharmacies.

Expected Outcomes: Real World Testing will demonstrate the PulseCheck ED e-prescribing module is conformant to §170.315(b)(3) with less than 25% error rate experienced by users. A successfully sent message indicates compliance to the ONC criteria. Additionally, successful messages demonstrate user's ability to perform functions within the intended eRx use case. All our e-prescribing transactions are transmitted to and from PulseCheck through Dr First Rcopia.

Prescription information is logged during usage of the module and reports will be run in client's environments to gather information. The prescription data will be analyzed and formatted for reporting purposes.

Errors will be reviewed as part of base line reporting for the initial testing year.

Real World Testing Measure #2

Measurement: Number of transmissions to public health agency (syndromic surveillance) messages created

Associated certification criteria: §170.315(f)(2) Transmission to public health agencies — syndromic surveillance

Description: This measure is tracking and counting how many syndromic surveillance messages are created successfully by PulseCheck ED over the course of a given interval.

Justification: This measure will provide a numeric value to indicate how often this interoperability feature is being used as well as its compliance to the requirement. An increment to this measure indicates that PulseCheck ED can successfully create syndromic messages for transmission to public health agencies. Syndromic surveillance enables faster and collaborative response from public health officials to support PulseCheck ED clients and their patients.

Expected Outcomes: The measurement will produce numeric results over a given interval. Real World Testing will demonstrate the ability of clients to use Syndromic Surveillance as described in § 170.315(f)(2). It is expected that PulseCheck ED will create Syndromic Surveillance messages with data as identified in the standards.

A successful measure increment indicates compliance to the underlying ONC criteria. It will show that PulseCheck ED can create a syndromic surveillance message, which can be used in means of health IT interoperability. Successfully completing this measure also implies users have a general understanding of the EMR functional operations for Syndromic Surveillance and an overall support for the user experience.

Reports will be run in client's environments and the data will be analyzed and formatted for reporting purposes.

We will use the measure count to establish a historic baseline of expected interoperability use so it can be used in subsequent real world testing efforts.